Tisdag 1 Juli | 00:13:43 Europe / Stockholm

Svenska | English

Oculis Holding

Filter

År

Typ

Språk

Rensa

2025-06-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2510,00 ISK | -1,18%

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08%

2025-06-05 10:00:00 Oculis birtir niðurstöður aðalfundar 2025 2450,00 ISK | +2,08%

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08%

2025-06-03 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2400,00 ISK | -0,83%

2025-06-03 10:00:00 Oculis to Participate in Upcoming June Investor Conferences 2420,00 ISK | -1,22%

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis birtir boð á aðalfund 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-07 10:00:00 Oculis to Present at Upcoming May Investor Conferences 2320,00 ISK | -2,52%

2025-05-01 10:00:00 Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

2025-04-25 22:00:00 Oculis Updates Share Capital 2290,00 ISK | +0,44%

2025-04-17 11:00:00 Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

2025-04-15 10:00:00 Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets 2280,00 ISK | +5,56%

2025-04-10 14:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68%

2025-04-10 10:00:00 Oculis lýkur innritun sjúklinga í báðar DIAMOND fasa 3 rannsóknirnar á OCS-01 sem meðferð við sjónhimnubjúg af völdum sykursýki 2040,00 ISK | +9,68%

2025-04-10 10:00:00 Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema 2040,00 ISK | +9,68%

2025-04-09 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2040,00 ISK | +9,68%

2025-04-01 10:00:00 Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond 2480,00 ISK | 0,00%

2025-03-20 23:01:00 Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities 2640,00 ISK | +2,33%

2025-03-14 21:31:47 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2500,00 ISK | -0,40%

2025-03-11 21:30:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2024 og kynnir áfanga í rekstri félagsins 2500,00 ISK | +2,46%

2025-03-11 21:30:00 Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update 2500,00 ISK | +2,46%

2025-03-05 10:00:00 Oculis to Present at Upcoming March Investor Conference 2620,00 ISK | +3,15%

2025-03-03 09:18:33 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2740,00 ISK | -0,72%

2025-02-14 01:40:48 Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum 3020,00 ISK | -1,31%

2025-02-14 01:40:48 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-14 01:39:36 Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares 3020,00 ISK | -1,31%

2025-02-08 00:35:06 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 3180,00 ISK | +0,63%

2025-01-31 22:00:00 Oculis updates share capital for its existing at-the-market offering program 3260,00 ISK | +3,82%

2025-01-21 22:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3240,00 ISK | +1,25%

2025-01-20 23:00:00 Oculis Publishes Notification of Major Changes in Voting Rights 3200,00 ISK | -1,23%

2025-01-06 09:53:25 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-04 00:48:20 Oculis Publishes Notification of Major Changes in Voting Rights 2470,00 ISK | +2,07%

2024-12-06 22:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2140,00 ISK | 0,00%

2024-11-29 10:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 2220,00 ISK | -0,89%

2024-11-27 10:15:47 Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities 2220,00 ISK | +4,72%

2024-11-13 10:00:00 Oculis to Present at the Stifel 2024 Healthcare Conference 2100,00 ISK | -2,78%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden